Kelun, Merck's lung cancer combo improves survival in late-stage China trial

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in ​patients with advanced lung cancer, meeting the main ‌goal of a late-stage study.